Forging a signature of in vivo senescence

Nature Reviews Cancer

Volumn 15, Issue 7, 2015, Pages 397-408

  Sharpless, Norman E ^a   Sherr, Charles J ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CELL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; BIOLOGICAL MARKER; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; PROTEIN P53;

CELL AGING; CELLULAR SENESCENCE; CHROMATIN; DNA DAMAGE; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENESCENCE; TELOMERE SHORTENING; ANIMAL; CELL CYCLE; GENETICS; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; BIOLOGICAL MARKERS; CELL AGING; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; GENES, P16; HUMANS; TELOMERE SHORTENING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84933050555     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3960     Document Type: Review

References (180)

1. Hayflick L. & Moorhead P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585-621 (1961
2. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614-636 (1965
3. Harley C. B., Futcher A. B. & Greider C. W. Telomeres shorten during aging of human fibroblasts. Nature 345, 458-460 (1990
4. Bodnar A. G., et al. Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349-352 (1998
5. Todaro G. J. & Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J. Cell Biol. 17, 299-313 (1963
6. Blasco M. A., et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91, 25-34 (1997
7. Harvey D. M. & Levine A. J. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5, 2375-2385 (1991
8. Serrano M., Lin A. W., McCurrach M. E., Beach D. & Lowe S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997
9. Kamijo T., et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659 (1997
10. Wright W. E. & Shay J. W. Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. Nat. Med. 6, 849-851 (2000
11. Sherr C. J. & DePinho R. A. Cellular senescence: mitotic clock or culture shock?. Cell 102, 407-410 (2000
12. Kuilman T., Michaloglou C., Mooi W. J. & Peeper D. S. The essence of senescence. Genes Dev. 24, 2463-2479 (2010
13. Rodier F. & Campisi J. Four faces of cellular senescence. J. Cell Biol. 192, 547-556 (2011
14. Campisi J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 75, 685-705 (2013
15. Collado M., Blasco M. A. & Serrano M. Cellular senescence in cancer and aging. Cell 130, 223-233 (2007
16. Kim W. Y. & Sharpless N. E. The regulation of INK4/ARF in cancer and aging. Cell 127, 265-275 (2006
17. Shay J. W., Pereira-Smith O. M. & Wright W. E. A role for both RB and p53 in the regulation of human cellular senescence. Exp. Cell Res. 196, 33-39 (1991
18. Beausour C. M., et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 22, 4212-4222 (2003
19. Sage J., Miller A. L., Péz-Mancera P. A., Wysocki J. M. & Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re entry. Nature 424, 223-228 (2003
20. Pardee A. B. G1 events and regulation of cell proliferation. Science 246, 603-608 (1989
21. Sherr C. J. & Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163 (1995
22. Blagosklonny M. V. Geroconversion: irreversible step to cellular senescence. Cell Cycle 13, 3628-3635 (2014
23. Blais A., van Oevelen C. J. C., Margueron R., Acosta-Alvear D. & Dynlacht B. D. Retinoblastoma tumor suppressor protein-dependent methylation of histone H3 lysine 27 is associated with irreversible cell cycle exit. J. Cell Biol. 179, 1399-1412 (2007
24. Burkhart D. L. & Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer 8, 671-682 (2008
25. Indovina P., Marcelli E., Casini N., Rizzo V. & Giordano A. Emerging roles of RB family: new defense mechanisms against tumor progression. J. Cell. Physiol. 228, 525-535 (2013
26. Kareta M. S., et al. Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. Cell Stem Cell 16, 39-50 (2015
27. Polyak K., et al. P27Kip1, a cyclin-Cdk inhibitor, links transforming growth-factor-β and contact inhibition to cell-cycle arrest. Genes Dev. 8, 9-22 (1994
28. Balciunaite E., et al. Pocket protein complexes are recruited to distinct targets in quiescent and proliferating cells. Mol. Cell. Biol. 25, 8166-8178 (2005
29. El Deiry W. S., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993
30. Harper J. W., Adami G. R., Wei N., Keyomarsi K. & Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816 (1993
31. Xiong Y., et al. p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704 (1993
32. Wang Y. A., Elson A. & Leder P. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc. Natl Acad. Sci. USA 94, 14590-14595 (1997
33. Deng C., Zhang P., Harper J. W., Elledge S. J. & Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684 (1995
34. Martín-Caballero J., Flores J. M., García-Palencia P. & Serrano M. Tumor susceptibility of p21Waf1/Cip1- deficient mice. Cancer Res. 61, 6234-6238 (2001
35. Pantoja C. & Serrano M. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 18, 4974-4982 (1999
36. Di Leonardo A., Linke S. P., Clarkin K. & Wahl G. M. DNA damage triggers a prolonged p53 dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8, 2540-2551 (1994
37. Sang L., Coller H. A. & Roberts J. M. Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science 321, 1095-1100 (2008
38. Spencer S. L., et al. The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit. Cell 155, 369-383 (2013
39. Krenning L., Feringa F. M., Shaltiel I. A., van Den Berg J. & Medema R. H. Transient activation of p53 in G2 phase is sufficient to induce senescence. Mol. Cell 55, 59-72 (2014
40. Alcorta D. A., et al. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl Acad. Sci. USA 93, 13742-13747 (1996
41. Robles S. J. & Adami G. R. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibrolasts. Oncogene 16, 1113-1123 (1998
42. Stein G. H., Drullinger L. F., Soulard A. & Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol. Cell. Biol. 19, 2109-2117 (1999
43. Johmura Y., et al. Necessary and sufficient role for a mitosis skip in senescence induction. Mol. Cell 55, 73-84 (2014
44. Gire V. & Dulic V. Senescence from G2 arrest, revisited. Cell Cycle 14, 297-304 (2015
45. Sherwood S. W., Rush D., Ellsworth J. L. & Schimke R. T. Defining cellular senescence in IMR 90 cells - a flow cytometric analysis. Proc. Natl Acad. Sci. USA 85, 9086-9090 (1988
46. Mao Z., Ke Z., Gorbunova V. & Seluanov A. Replicatively senescent cells are arrested in G1 and G2 phases. Aging 4, 431-435 (2012
47. Wagner M., et al. Replicative senescence of human endothelial cells in vitro involves G1 arrest, polyploidization and senescence-associated apoptosis. Exp. Gerontol. 36, 1327-1347 (2001
48. Takahashi A., et al. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat. Cell Biol. 8, 1291-1297 (2006
49. Aksoy O., et al. The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence. Genes Dev. 26, 1546-1557 (2012
50. Lanni J. S. & Jacks T. Characterization of the p53 dependent postmitotic checkpoint following spindle disruption. Mol. Cell. Biol. 18, 1055-1064 (1998
51. Hayashi M. T. & Karlseder J. DNA damage associated with mitosis and cytokinesis failure. Oncogene 32, 4593-4601 (2013
52. Coppe J. P., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853-2868 (2008
53. Rodier F., et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 11, 973-979 (2009
54. Narita M., et al. Rb mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703-716 (2003
55. Bartkova J., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633-637 (2006
56. Di Micco R., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638-642 (2006
57. Rodier F., et al. DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J. Cell Sci. 124, 68-81 (2011
58. Fumagalli M., Rossiello F., Mondello C. & di Fagagna F. D. Stable cellular senescence is associated with persistent DDR activation. PLoS ONE 9, e110969 (2014
59. Dimri G. P., et al. A biomarker that identifies senescent human-cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363-9367 (1995
60. Itahana K., Campisi J. & Dimri G. P. Methods to detect biomarkers of cellular senescence: the senescence-associated β-galactosidase assay. Methods Mol. Biol. 371, 21-31 (2007
61. Kurz D. J., Decary S., Hong Y. & Erusalimsky J. D. Senescence-associated β-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J. Cell Sci. 113, 3613-3622 (2000
62. Lee B. Y., et al. Senescence-associated β-galactosidase is lysosomal β-galactosidase. Aging Cell 5, 187-195 (2006
63. Coates P. J., Lorimore S. A., Rigat B. A., Lane D. P. & Wright E. G. Induction of endogenous β-galactosidase by ionizing radiation complicates the analysis of p53-lacZ transgenic mice. Oncogene 20, 7096-7097 (2001
64. Bursuker I., Rhodes J. M. & Goldman R. β-galactosidase - an indicator of the maturational stage of mouse and human mononuclear phagocytes. J. Cell. Physiol. 112, 385-390 (1982
65. Kopp H. G., Hooper A. T., Shmelkov S. V. & Rafii S. β-galactosidase staining on bone marrow. The osteoclast pitfall. Histol. Histopathol. 22, 971-976 (2007
66. Young A. R. J. & Narita M. Connecting autophagy to senescence in pathophysiology. Curr. Opin. Cell Biol. 22, 234-240 (2010
67. Dorr J. R., et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 501, 421-425 (2013
68. Ivanov A., et al. Lysosome-mediated processing of chromatin in senescence. J. Cell Biol. 202, 129-143 (2013
69. Serrano M., Hannon G. J. & Beach D. A new regulatory motif in cell-cycle control causing specific-inhibition of cyclin D/CDK4. Nature 366, 704-707 (1993
70. Hannon G. J. & Beach D. p15INK4b is a potential effector of TGF-β-induced cell-cycle arrest. Nature 371, 257-261 (1994
71. Quelle D. E., Zindy F., Ashmun R. A. & Sherr C. J. Alternative reading frames of the INK4a tumor-suppressor gene encode two unrelated proteins capable of inducing cell-cycle arrest. Cell 83, 993-1000 (1995
72. Pomerantz J., et al. The Ink4a tumor suppressor gene product, 19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723 (1998
73. Zhang Y., Xiong Y. & Yarbrough W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734 (1998
74. Kamijo T., et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl Acad. Sci. USA 95, 8292-8297 (1998
75. Chandler H. & Peters G. Stressing the cell cycle in senescence and aging. Curr. Opin. Cell Biol. 25, 765-771 (2013
76. Bignell G. R., et al. Signatures of mutation and selection in the cancer genome. Nature 463, 893-898 (2010
77. Beroukhim R., et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010
78. Rheinwald J. G., et al. A two-stage, p16INK4A- and p53 dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol. Cell. Biol. 22, 6930-6930 (2002
79. Herbig U., Jobling W. A., Chen B. P. C., Chen D. J. & Sedivy J. M. Telomere shortening triggers senescence of human cells through a pathway involving ATM, 53, and p21CIP1, but not p16INK4A. Mol. Cell 14, 501-513 (2004
80. Yamakoshi K., et al. Real-time in vivo imaging of p16Ink4a reveals cross talk with p53. J. Cell Biol. 186, 393-407 (2009
81. Krimpenfort P., et al. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 448, 943-946 (2007
82. Kuilman T., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019-1031 (2008
83. Cudejko C., et al. p16INK4a deficiency promotes IL 4 induced polarization and inhibits proinflammatory signaling in macrophages. Blood 118, 2556-2566 (2011
84. Wiedemeyer R., et al. Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell 13, 355-364 (2008
85. Shapiro G. I., et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 55, 505-509 (1995
86. Khleif S. N., et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F mediated induction of cyclin kinase inhibitor activity. Proc. Natl Acad. Sci. USA 93, 4350-4354 (1996
87. Nakao Y., et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br. J. Cancer 75, 1410-1416 (1997
88. Witkiewicz A. K., Knudsen K. E., Dicker A. P. & Knudsen E. S. The meaning of p16ink4a expression in tumors: functional significance, clinical associations and future developments. Cell Cycle 10, 2497-2503 (2011
89. Ohtani N., Yamakoshi K., Takahashi A. & Hara E. Real-time in vivo imaging of p16Ink4a gene expression: a new approach to study senescence stress signaling in living animals. Cell Div. 5, 1 (2010
90. Baker D. J., et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479, 232-236 (2011
91. Demaria M., et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF AA. Dev. Cell 31, 722-733 (2014
92. Burd C. E., et al. Monitoring tumorigenesis and senescence in vivo with a p16INK4a-luciferase model. Cell 152, 340-351 (2013
93. Zindy F., Quelle D. E., Roussel M. F. & Sherr C. J. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15, 203-211 (1997
94. Krishnamurthy J., et al. Ink4a/Arf expression is a biomarker of aging. J. Clin. Invest. 114, 1299-1307 (2004
95. Waaijer M. E., et al. The number of p16INK4a positive cells in human skin reflects biological age. Aging Cell 11, 722-725 (2012
96. Sorrentino J. A., et al. p16INK4a reporter mice reveal age-promoting effects of environmental toxicants. J. Clin. Invest. 124, 169-173 (2014
97. Natarajan E., et al. Co expression of p16INK4A and laminin 5 ?2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture. Am. J. Pathol. 163, 477-491 (2003
98. Jun J. I. & Lau L. F. Cellular senescence controls fibrosis in wound healing. Aging 2, 627-631 (2010
99. Jun J. I. & Lau L. F. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat. Cell Biol. 12, 676-685 (2010
100. Lemster B. H., et al. Induction of CD56 and TCR-independent activation of T cells with aging. J. Immunol. 180, 1979-1990 (2008
101. Liu Y., et al. Expression of p16INK4a in peripheral blood T cells is a biomarker of human aging. Aging Cell 8, 439-448 (2009
102. Liu Y., et al. Expression of p16INK4a prevents cancer and promotes aging in lymphocytes. Blood 117, 3257-3267 (2011
103. Migliaccio M., Raj K., Menzel O. & Rufer N. Mechanisms that limit the in vitro proliferative potential of human CD8+ T lymphocytes. J. Immunol. 174, 3335-3343 (2005
104. Erickson S., et al. Involvement of the Ink4 proteins p16 and p15 in T lymphocyte senescence. Oncogene 17, 595-602 (1998
105. Schmitt C. A., et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346 (2002
106. Sanoff H. K., et al. Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J. Natl Cancer Inst. 106, dju057 (2014
107. Nelson J. A. E., et al. Expression of p16INK4a as a biomarker of T cell aging in HIV-infected patients prior to and during antiretroviral therapy. Aging Cell 11, 916-918 (2012
108. Signer R. A. J., Montecino-Rodriguez E., Witte O. N. & Dorshkind K. Aging and cancer resistance in lymphoid progenitors are linked processes conferred by p16Ink4a and Arf. Genes Dev. 22, 3115-3120 (2008
109. Jaruga E., Skierski J., Radziszewska E. & Sikora E. Proliferation and apoptosis of human T cells during replicative senescence - a critical approach. Acta Biochim. Polon. 47, 293-300 (2000
110. Shi L., et al. KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection. J. Immunol. 192, 649-657 (2014
111. Di Mitri D., et al. Reversible senescence in human CD4+CD45RA+CD27- memory T cells. J. Immunol. 187, 2093-2100 (2011
112. Liu Y. & Sharpless N. E. Tumor suppressor mechanisms in immune aging. Curr. Opin. Immunol. 21, 431-439 (2009
113. Akbar A. N. & Henson S. M. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?. Nat. Rev. Immunol. 11, 289-295 (2011
114. D'Adda di Fagagna F., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198 (2003
115. Takai H., Smogorzewska A. & de Lange T. DNA damage foci at dysfunctional telomeres. Curr. Biol. 13, 1549-1556 (2003
116. Nakamura A. J., et al. Both telomeric and non-telomeric DNA damage are determinants of mammalian cellular senescence. Epigenetics Chromatin 1, 6 (2008
117. Halazonetis T. D., Gorgoulis V. G. & Bartek J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352-1355 (2008
118. Bakkenist C. J. & Kastan M. B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499-506 (2003
119. Munro J., Barr N. I., Ireland H., Morrison V. & Parkinson E. K. Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16 dependent mechanism that is independent of a mitotic clock. Exp. Cell Res. 295, 525-538 (2004
120. Kosar M., et al. Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type- and insult-dependent manner, and follow expression of p16ink4a. Cell Cycle 10, 457-468 (2011
121. Di Micco R., et al. Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat. Cell Biol. 13, 292-302 (2011
122. Kennedy A. L., et al. Senescent mouse cells fail to overtly regulate the HIRA histone chaperone and do not form robust Senescence Associated Heterochromatin Foci. Cell Div. 5, 16 (2010
123. Trimarchi J. M. & Lees J. A. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol. 3, 11-20 (2002
124. Chandra T., et al. Independence of repressive histone marks and chromatin compaction during senescent heterochromatic layer formation. Mol. Cell 47, 203-214 (2012
125. Chandra T. & Narita M. High-order chromatin structure and the epigenome in SAHFs. Nucleus 4, 23-28 (2013
126. Chien Y. C., et al. Control of the senescence-associated secretory phenotype by NF ?B promotes senescence and enhances chemosensitivity. Genes Dev. 25, 2125-2136 (2011
127. Acosta J. C., et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 15, 978-990 (2013
128. Xue W., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007
129. Krizhanovsky V., et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134, 657-667 (2008
130. Lujambio A., et al. Non-cell-autonomous tumor suppression by p53. Cell 153, 449-460 (2013
131. Krtolica A., Parrinello S., Lockett S., Desprez P. Y. & Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA 98, 12072-12077 (2001
132. Kang T. W., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547-551 (2011
133. Ye J., et al. Human regulatory T cells induce T lymphocyte senescence. Blood 120, 2021-2031 (2012
134. Braumuller H., et al. T helper 1 cell cytokines drive cancer into senescence. Nature 494, 361-365 (2013
135. Neves J., Demaria M., Campisi J. & Jasper H. Of flies, mice, and men: evolutionarily conserved tissue damage responses and aging. Dev. Cell 32, 9-18 (2015
136. Wolf J., Rose-John S. & Garbers C. Interleukin 6 and its receptors: a highly regulated and dynamic system. Cytokine 70, 11-20 (2014
137. Ataie-Kachoie P., Pourgholami M. H., Richardson D. & Morris D. L. Gene of the month: Interleukin 6 (IL 6). J. Clin. Pathol. 67, 932-937 (2014
138. Blackburn E. H. Structure and function of telomeres. Nature 350, 569-573 (1991
139. Lansdorp P. M. Telomeres and disease. EMBO J. 28, 2532-2540 (2009
140. Artandi S. E. & DePinho R. A. Telomeres and telomerase in cancer. Carcinogenesis 31, 9-18 (2010
141. Shay J. W. & Wright W. E. Role of telomeres and telomerase in cancer. Semin. Cancer Biol. 21, 349-353 (2011
142. Jaskelioff M., et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 469, 102-106 (2011
143. Armanios M. Telomeres and age-related disease: how telomere biology informs clinical paradigms. J. Clin. Invest. 123, 996-1002 (2013
144. Aubert G., Hills M. & Lansdorp P. M. Telomere length measurement - caveats and a critical assessment of the available technologies and tools. Mutat. Res. 730, 59-67 (2012
145. Hewitt G., et al. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat. Commun. 3, 708 (2012
146. Rudolph K. L., et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96, 701-712 (1999
147. Collado M., et al. Tumour biology - senescence in premalignant tumours. Nature 436, 642-642 (2005
148. Munoz-Espin D., et al. Programmed cell senescence during mammalian embryonic development. Cell 155, 1104-1118 (2013
149. Storer M., et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 155, 1119-1130 (2013
150. Huang T. & Rivera-Pérez J. A. Senescence-associated β-galactosidase activity marks the visceral endoderm of mouse embryos but is not indicative of senescence. Genesis 52, 300-308 (2014
151. Li C., Finkelstein D. & Sherr C. J. Arf tumor suppressor and miR 205 regulate cell adhesion and formation of extraembryonic endoderm from pluripotent stem cells. Proc. Natl Acad. Sci. USA 110, E1112-E1121 (2013
152. Michaloglou C., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724 (2005
153. Gray-Schopfer V. C., et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16?. Br. J. Cancer 95, 496-505 (2006
154. Vredeveld L. C., et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 26, 1055-1069 (2012
155. Damsky W., et al. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell 27, 41-56 (2015
156. Sharpless N. E. & Depinho R. A. How stem cells age and why this makes us grow old. Nat. Rev. Mol. Cell Biol. 8, 703-713 (2007
157. Munoz-Espin D. & Serrano M. Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15, 482-496 (2014
158. Martin N., Beach D. & Gill J. Ageing as developmental decay: insights from p16INK4a. Trends Mol. Med. 20, 667-674 (2014
159. van Deursen J. M. The role of senescent cells in ageing. Nature 509, 439-446 (2014
160. Signer R. A. J. & Morrison S. J. Mechanisms that regulate stem cell aging and life span. Cell Stem Cell 12, 152-165 (2013
161. Zhu Y., et al. The Achilles heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell http://dx.doi.org/10.1111/acel.12344 (2015
162. González-Navarro H., et al. p19ARF deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J. Am. Coll. Cardiol. 55, 2258-2268 (2010
163. Herbig U., Ferreira M., Condel L., Carey D. & Sedivy J. M. Cellular senescence in aging primates. Science 311, 1257 (2006
164. Ershler W. B. & Keller E. T. Age-associated increased interleukin 6 gene expression, late-life diseases, and frailty. Annu. Rev. Med. 51, 245-270 (2000
165. Krishnamurthy J., et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 443, 453-457 (2006
166. Janzen V., et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 443, 421-426 (2006
167. Molofsky A. V., et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 443, 448-452 (2006
168. Chen H., et al. PDGF signalling controls age-dependent proliferation in pancreatic β-cells. Nature 478, 349-355 (2011
169. Cosgrove B. D., et al. Rejuvenation of the muscle stem cell population restores strength to injured aged muscles. Nat. Med. 20, 255-264 (2014
170. Sousa-Victor P., et al. Geriatric muscle stem cells switch reversible quiescence into senescence. Nature 506, 316-321 (2014
171. Berent-Maoz B., Montecino-Rodriguez E., Signer R. A. J. & Dorshkind K. Fibroblast growth factor 7 partially reverses murine thymocyte progenitor aging by repression of Ink4a. Blood 119, 5715-5721 (2012
172. Baker D. J., et al. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat. Cell Biol. 10, 825-836 (2008
173. Jeck W. R., Siebold A. P. & Sharpless N. E. Review: a meta-analysis of GWAS and age-associated diseases. Aging Cell 11, 727-731 (2012
174. Sherr C. J. Ink4-Arf locus in cancer and aging. Wiley Interdiscip. Rev. Dev. Biol. 1, 731-741 (2012
175. LaPak K. M. & Burd C. E. The molecular balancing act of p16INK4a in cancer and aging. Mol. Cancer Res. 12, 167-183 (2014
176. Henson J. D., Neumann A. A., Yeager T. R. & Reddel R. R. Alternative lengthening of telomeres in mammalian cells. Oncogene 21, 598-610 (2002
177. O'Sullivan R. J. & Almouzni G. Assembly of telomeric chromatin to create ALTernative endings. Trends Cell Biol. 24, 675-685 (2014
178. Cho N. W., Dilley R. L., Lampson M. A. & Greenberg R. A. Interchromosomal homology searches drive directional ALT telomere movement and synapsis. Cell 159, 108-121 (2014
179. Boquoi A., et al. Reversible cell cycle inhibition and premature aging features imposed by conditional expression of p16Ink4a. Aging Cell 14, 139-147 (2015
180. Althubiti M., et al. Characterization of novel markers of senescence and their prognostic potential in cancer. Cell Death Dis. 5, e1528 (2014